Abstract: 　Objective　To?explore?the?effect?of?tyrosine?kinase?inhibitor?on?height?growth?in?children?with?acute?myeloid? leukemia. Method? The?clinical?data?of?a?child?with?height?growth?retardation?caused?by?tyrosine?kinase?inhibitor?were? retrospectively?analyzed,?and?the?relevant?review?was?reviewed.?Results? The?female?child?had?a?fraternal?twin?sister?with?similar? body?weight?at?birth.?At?the?age?of?19?months,?the?child?was?diagnosed?of?acute?myeloid?leukemia?by?clinical,?blood?routine,?bone? marrow?morphology,?immunology,?molecular， ?and?genetic?genetics.?Genetic?detection?showed?CBFβ-MYH11?fusion?gene?(531.8%)? and?positive?c-kitD419-L42 1delins WN,?and?the?child?received?routine?chemotherapy.?At?that?time,?the?height?of?the?child?and?her? sibling?were?both?at?the?P90?of?the?growth?curve?of?the?same?age?and?sex?in?China.?The?child’s?bone?marrow?was?completely?relieved? after?induction?chemotherapy,?but?the?CBF -MyH11?gene?did?not?turn?negative.?After?the?consolidation?chemotherapy,?the?treatment? with?imatinib?was?added?and?the?gene?turned?negative,?but?the?child?showed?slower?growth?in?height?(from?P90 to P75).?After?the? cessation?of?imatinib,?the?growth?rate?of?height?recovered.?However,?due?to?intermittent?positive?of?CBFβ-MYH11?gene,?imatinib? was?added,?and?the?height?growth?was?reduced.?With?dasatinib?to?replace?imatinib,?the?increase?in?height?was?still?slowed?down.?At?9? years?and?10?months?of?the?follow-up,?the?height?of?the?child?was?134?cm?at?P10~P25,?while?her?sibling?sister?was?146?cm,?still?at?P90. Conclusion? Tyrosine?kinase?inhibitors?can?cause?height?growth?retardation?in?acute?myeloid?leukemia?child.

Key words: 　tyrosine?kinase?inhibitor;? acute?myeloid?leukemia;? height;? child